JP2005508322A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508322A5
JP2005508322A5 JP2003530213A JP2003530213A JP2005508322A5 JP 2005508322 A5 JP2005508322 A5 JP 2005508322A5 JP 2003530213 A JP2003530213 A JP 2003530213A JP 2003530213 A JP2003530213 A JP 2003530213A JP 2005508322 A5 JP2005508322 A5 JP 2005508322A5
Authority
JP
Japan
Prior art keywords
suramin
agent
interleukin
kit
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/030210 external-priority patent/WO2003026574A2/en
Publication of JP2005508322A publication Critical patent/JP2005508322A/ja
Publication of JP2005508322A5 publication Critical patent/JP2005508322A5/ja
Pending legal-status Critical Current

Links

JP2003530213A 2001-09-24 2002-09-24 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分 Pending JP2005508322A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32470401P 2001-09-24 2001-09-24
PCT/US2002/030210 WO2003026574A2 (en) 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Publications (2)

Publication Number Publication Date
JP2005508322A JP2005508322A (ja) 2005-03-31
JP2005508322A5 true JP2005508322A5 (enExample) 2006-01-12

Family

ID=23264730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003530213A Pending JP2005508322A (ja) 2001-09-24 2002-09-24 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分

Country Status (9)

Country Link
US (2) US20040180955A1 (enExample)
EP (1) EP1429713A4 (enExample)
JP (1) JP2005508322A (enExample)
KR (1) KR20040062546A (enExample)
CN (1) CN100441176C (enExample)
AU (1) AU2002330088B2 (enExample)
CA (1) CA2461227C (enExample)
IL (1) IL161036A0 (enExample)
WO (1) WO2003026574A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007065016A2 (en) * 2005-12-02 2007-06-07 Au Jessie L S Methods and compositions to improve activity and reduce toxicity of stents
KR20140098185A (ko) * 2007-07-30 2014-08-07 아디아 바이오사이언스즈 인크. 다형체를 포함하는, mek의 억제제로서의 n-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
PH12018501678B1 (en) 2011-08-30 2022-08-10 Astex Pharmaceuticals Inc Decitabine derivative formulations
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
EP3316685A4 (en) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilized Pharmaceutical Compositions
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
JP2022145629A (ja) * 2021-03-18 2022-10-04 学校法人産業医科大学 スラミンを含む組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597830A (en) * 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
ES2248847T3 (es) * 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
ATE241993T1 (de) * 1997-03-11 2003-06-15 Aeterna Lab Inc Zubereitungen zur tumorbehandlung enthaltend hai- knorpelextrakte und antineoplastische mittel
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
AU780454B2 (en) * 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same

Similar Documents

Publication Publication Date Title
JP5846822B2 (ja) 栄養又は治療組成物
CA2461227A1 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
Johnson Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies
JP2017519753A5 (enExample)
US5854231A (en) Pharmaceutical composition for inhibiting the growth of cancers
ES2200316T3 (es) Composiciones para tratar tumores que contienen extractos de cartilago de tiburon y agentes antineoplasticos.
RU2016133168A (ru) Изоксазолиновые композиции и их применение в качестве противопаразитарных средств
HRP20110245T1 (hr) Derivati pirazolopirimidina kao inhibitori o ciklinu ovisne kinaze
RU2006146619A (ru) Лечение гемцитабином и ингибитором рецептора эпидермального фактора роста(egfr)
JP2006507308A5 (enExample)
RU2003108822A (ru) Улучшенная противоопухолевая композиция на основе паклитаксела
CN102688492A (zh) 包含四环素类的抗炎组合物及其用途
RU2005114018A (ru) Эпотилон d+фторурацил/гемцитабин
JP2004501870A5 (enExample)
CA2672839A1 (en) Treatment of lung cancer with s-farnesylthiosalicylic acid and analogs thereof
RU2010145048A (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
JP2009511590A5 (enExample)
JPWO2007108272A1 (ja) 癌治療用キットおよび癌治療用医薬組成物
JP2025111546A (ja) Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質
US20050203174A1 (en) Combination therapies using leptomycin B
SK5032003A3 (en) Antitumor therapy comprising distamycin derivatives
JPH0586376B2 (enExample)
KR20100054210A (ko) 암 치료를 위한 육산화사비소의 병용요법
CN1615136A (zh) 包含埃坡霉素和抗代谢物的组合
JP2007525507A5 (enExample)